Final Program [International Conference on AIDS (14th: 2002: Barcelona, Spain)]

Poster Exhibitions

Monday Ju8

Poster Exhibitions Monday IuIv 8

Monday

MoPeA3o75 Enhancement of nasally administered HIV
peptide immunogenicity using a polysaccharide
bioadhesive
S K Nordone H F Staats (United States)
MoPeA3o76 Identification and optimisation of novel HLA-A2
binding, HIV-derived CTL epi-topes using Artificial
Neural Networks (ANN), and their
immunogenicity in HLA-A2 transgenic mice
S L Corbet H V Nielsen, L Vinner, S L Lauemoller,
D Terrien, S Tang, P Chaplin, S Brunak, S Buus,
A Fomsgaard (Denmark)
MoPeA3o77 In vivo induction of CTLs and neutralizing
antibodies by a candidate anti-HIV-1 vaccine
based on Virus-like Particles presenting a gp12o
molecule from a HIV-1 isolate of clade A (HIVVLPAs)
L Buonaguro', M L Tornesello', L Racioppi',
B Biryahwaho2, SD K Sempala2, FM Buonaguroa'
(Italy; 2Uganda)
MoPeA3o78 Enhanced Immune responses induced by
optimized plasmid vaccines encoding IL-15 or
engineered B7 costimulatory molecules
I Boyer', C Chattergoon', M Agadjanian',
M Holterman', M Kutzler', J Eldridge', Z Israel',
J Kim', G Pavlakis', R Sekaly2, DB Weiner'
('United States; 2Canada)
MoPeA3o79 Quantitative in vitro challenge assay for vaccine
evaluation
R John, S Arango-jaramillo, DH Schwartz
(United States)
MoPeA3o8o First round suppression of GFP-expressing HIV in
resistant PBMCs
S lyengar, J G Finny, D H Schwartz (United States)
MoPeA3o81 Gp41 specific IgA of HIV-Exposed-Uninfected
individuals and of immunized mice inhibit HIV
viral replication of different strains
L Lopalco, C Barassi, C Pastore, R Longhi,
M Clerici (Italy)
MoPeA3o82 HIV-specific effector responses in parenterally
and mucosally exposed uninfected individuals
G Makedonas', J Bruneau', R Sekaly', M Alary',
F Lamothe', C Lowndes2, N F Bernard'
('Canada; 2United Kingdom)
MoPeA3o83 Escape in one of two novel CTL epitopes
restricted by a common macaque MHC class I
molecule: implications for vaccine studies
TU Vogel, TC Friedrich, D H O'Connor,
W Rehrouer, H Horton, K Vielhuber, E JDodds,
R Rudersdorf, TM Allen, N Wilson, D I Watkins
(United States)
MoPeA3o84 HIV envelope derived vaccines induce persistent
T helper cell response
K K Murthy, K E Cobb, M TSalas, HM McClure,
S Gonzales, S P Fargo (United States)
MoPeA3o85 Russian H IV vaccine initiative
A P Kozlov (Russian Federation)
MoPeA3o86 HLA-g is expressed in PBMC from HIV-i+
individuals
I Pena, M Lozano, R Gonzales, G Duenas,
I M Kindelan, R Caballos, E Vidal, N Rouas-Freiss,
R M SantaMaria, R Solona, ED Carosella (Spain)
MoPeA3o87 Selective depletion of CD56dim NK cell subsets
and maintenance of CD56bright NK cells in
treatment-naive H IV-1 seropositive individuals
I Pena, I G Casado, 0 Delarosa, M D Galiani,
R Gonzalez, R Solana, I Torre-Cisneros,
I L Villanueva, B Sanchez (Spain)

MoPeB3o88 Evaluation of three rapid tests for detection of
antibodies to HIV-1 non-B subtypes
A Holguin V Soriano (Spain)

MoPeB3o89 The Atlantic Study: A randomized, open-label trial
comparing two protease inhibitor (PI)-sparing
antiretroviral strategies versus a standard
PI-containing regimen, 2 year follow-up data
R van Leeuwen (The Netherlands)
MoPeB3o9o Sensitivity of rapid antibody tests for HIV
serovoncersion
B M Branson N K Meredith, J V Mei (United States)
MoPeB3o91 Rapid HIV-i diagnostic algorithms for use in HIV
infection screening
E K Calero, JA Malia, R Sawyer, L Brown, D L Birx,
B Branson, N L Michael (United States)
MoPeB3o92 Utility of rapid HIV testing in rural settings
S C Shah', A Haag2, A Purohit2, R M Shah',
V Gaur' ('India; 2United States)
MoPeB3o93 Evaluation of determine HIV-1/2 rapid assay
using fresh routine specimens in Uganda, Kenya
and South Africa
H Arai', T Imai, T Tanimoto', C Ducar,
P Kataaha2, B Jackson3, A 0 Misore4,
E J V Rensburg5, D York, K Takedao' (Japan;
2Uganda; 3United States; 4Kenya; 5South Africa)
MoPeB3o94 Evaluating rapid HIV testing techniques for
surveillance in Dominican Republic
E Gomez M Almanzar, A Ramirez, KAlcantara
(Dominican Republic)
MoPeB3o95 Performance of the rapid Abbott DetermineTM
HIV-1/2 (AD) test during primary HIV-1 infection
M G Miguez, I Zapiola, S Ferndndez Giuliano,
L Mammana, G Juncos, M Pugliese, S Multare,
M B Bouzas (Argentina)
MoPeB3o96 Evaluation of a new combined antigen and
antibody human immunodeficiency virus
screening assay VIDAS HIV DUO Ultra
B Weber', A Berger2, H Rabenau2, H Doerr2
(Luxembourg; 2Germany)
MoPeB3o97 Design, preparation and characterization of
molecular beacons for real-time HIV-1 NASBA
applications
P Sillekens, R van Beers, J van der Schoot,
L van Nes, P Hiemstra, H van Schijndel, F Venema
(The Netherlands)
MoPeB3o98 Heat-denatured HIV-1 p24 antigen predicts
disease progression and correlates with HIV-1
RNA and CD4+ T-lymphocyte level in adults with
early-stage disease
T R Sterlinq, D R Hoover', Astemborski',
D Vlahov, I G Bartlett', S Strathdee',
J Schupbach2 (United States; 2Switzerland)
MoPeB3o99 Correlation between total lymphocyte counts and
CD4 counts in HIV-1 positive adults in Yaounde
D N S Mbanya, F K Assah, L N Kaptue (Cameroon)
MoPeB31oo Absolute or total lymphocyte count as a marker
for initiating highly active antiretroviral therapy
MA jacobson, L Liu, H Khayam-Bashi, S Deeks,
C Hinger, I Kahn (United States)
MoPeB31ol Usefulness of indirect markers for identifying
patients severely immunocompromised in rural
Malawi
I M Tassie', T Marquardt2, M Abele2
D Odhiambo2, H Damisoni2, S Rehmet
M Mulemba2 (France; 2Molowi)
MoPeB31o2 Diastolic dysfunction in human immunodeficiency
virus (H IV) infected patients in South Asia
N Wig, CM Mittal, S Mishra, R M Pandey, P Arora
(India)
MoPeB31o3 The benefit of using total lymphocyte count for

monitoring the treatment of HIV/AIDS patients in
Thailand
S Kohreanudom (Thailand)

Final Program